Leukemia: A model for drug development

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2598-2604

  Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLUDARABINE PHOSPHATE; GUANOSINE DERIVATIVE; MERCAPTOPURINE; MITOXANTRONE; NELARABINE; PENTOSTATIN; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG DESIGN; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA; MICE; SURVIVAL ANALYSIS;

EID: 0031408112     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Skipper, H. E., Schabel, F. M., Jr., and Wilcox, W. S. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep., 35: 1-111, 1964.
2. Frei, E., III. Confrontation, passion, and personalization. Clin. Cancer Res., 3: 2554-2562, 1997.
3. Frei, E. III, Karon, M., Levin, R. H., et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood, 26: 642, 1965.
4. Kurzrock, R., Strom, S. S., Estey, E., O'Brien S., Keating, M. J., Jiang, Hong, Adams, T., and Talpaz, M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J. Clin. Oncol., 15: 1803-1810, 1997.
5. Keating, M. J., McCredie, K. B., Bodey, M. D., Smith, T., Gehan, E., and Freireich, E. J. Improved aspects for long-term survival in adults with acute myelogenous leukemia. J. Am. Med. Assoc., 248: 2481-2486, 1982.
6. Yates, J. W., Wallace, H. J., Jr., Ellison, R. R., and Holland, J. F. 1-β-D-arabinofuranosylcytosine (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep., 57: 485-488, 1973.
7. Rodriguez, V., Bodey, G. P., Gutterman, J. U., McCredie, K. B., and Freireich, E. J. Combination chemotherapy of adult acute leukemia for remission induction and maintenance. In: F. Mandelli, S. Amadori, and G. Mariani (eds.), Therapy of Acute Leukemias: Proceedings of the First International Symposium of Treatment of Acute Leukemias, pp. 569-577. Rome: Centro Minerva Medica, 1975.
8. McCredie, K. B., Bodey, G. P., Freireich, E. J, Hester, J. P., Rodriguez, V., and Keating, M. J. Chemoimmunotherapy of adult acute leukemia. Cancer (Phila.), 47: 1256-1261, 1981.
9. Holmes, R., et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16) (p13a22). Blood, 65: 1017-1020, 1985.
10. Trujillo, J. M., Cork, A., Ahearn, M. J., Youness, E. L., and McCredie, K. B. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood, 53: 695-706, 1979.
11. Larson, R. A., Kondo, K., Vardiman, J. W., Butler, A. E., Golomb, H., and Rowley, J. D. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med., 76: 827-841, 1984.
12. Kantarjian, H. M., Estey, E., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S., McCredie, K. B., and Freireich, E. J. Phase I-II and cellular pharmacology study of high dose 1-β-D-arabinofuranosylcytosine in refractory leukemia. Am. J. Med., 81: 387-394, 1986.
13. Mayer, R. J., David, R. B., Schiffer, C. A., Berg, D. T., Pomell, B. L., Schulman, P., Omura, G. A., Moure, J. O., McIntyre, O. R., and Frei, E, III. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 331: 896-903, 1994.
14. Keating, M. J., Estey, E., Plunkett, W., Iacoboni, S., Walters, R., Kantarjian, H., Andersson, B., Beran, M., McCredie, K. B., and Freireich, E. J Evolution of clinical studies with high-dose 1-β-D-arabinofuranosylcytosine (ara-C) at the M. D. Anderson Hospital. Semin. Oncol., 12 (Suppl. 3): 98-104, 1985.
15. Bernard, J., Weil, M., Boiron, M., Jacquillat, C., Flandrin, G., and Gemon, M. Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood, 41: 489-496, 1973.
16. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, H. X., Zoha, L., Gu, L. J., and Wang, Z. I. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
17. Degos, L., Chomienne, C., Ballerini, P., Huang, M. E., Daniel, M. T., Berger, R., and Castaigne, S. All-trans retinoic acid: a novel differentiation therapy for acute promyelocytic leukemia. Am. Soc. Clin. Oncol., 9: 207, 1990.
18. Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrel, R. P., Jr., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., and Evans, R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukaemia fuses RAR-α with a novel putative transcription factor, PML. Cell, 66: 663-674, 1991.
19. Fenaux, P., Le Deley, M. C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M. T., Bowen, D., Guebner, G., Bauters, F., Fegueux, N., Fey, M., Sanz, M., Lowenberg, B., Maloisel, F., Auzanneau, G., Sadoun, A., Gardin, C., Bastion, Y., Ganser, A., Jacky, E., Dombret, H., Chastang, C., and Degos, L. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood, 82: 3241-3249, 1993.
20. Ghaddar, H. M., Plunkett, W., Kantarjian, H. M., Pierce, S., Freireich, E. J, Keating, M. J., and Estey, E. H. Long-term results following treatment of newly diagnosed acute myelogenous leukemia with continuous infusion high-dose 1-β-D-arabinofuranosylcytosine. Leukemia (Baltimore), 8: 1269-1274, 1994.
21. 3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-3353, 1997.
22. Montgomery, J. A., Clayton, S. D., Shortnacy, A. T., and Hewson, K. An improved procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine. J. Heterocycl. Chem., 16: 157-160, 1979.
23. Von Hoff, D. D. Phase I clinical trials with fludarabine phosphate. Semin. Oncol., 17: 3-17, 1990.
24. Grever, M., Leiby, J., Kraut, E., Metz, E., Neidhart, J., Balcerzak, S., and Malspeis, L. A comprehensive Phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol., 17: 39-48, 1990.
25. Redman, J. R., Cabanillas, F., Velasquez, W. S., McLaughlin, P., Hagemeister, F. B., Swan, F., Jr., Rodriguez, M. A., Plunkett, W. K., and Keating, M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective agent in low-grade lymphoma. J. Clin. Oncol., 10: 790-794, 1992.
26. Chun, H. G., Leyland-Jones, B. R., Caryk, S. M., and Hoth, D. F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep., 70: 1225-1228, 1986.
27. Grever, M. R., Kopecky, K. J., Coltman, C. A., Files, J. C., Greenberg, B. R., Hutton, J. J., Talley, R., Von Hoff, D. D., and Balcerak, S. P. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol., 30: 457-459, 1988.
28. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J, and McCredie, K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74: 19-25, 1989.
29. Huang, P., and Wright, S. Induction of apoptosis by nucleoside analogs. In: B. D. Cheson, M. J. Keating, and W. Plunkett (eds.), Nucleoside Analogs in Cancer Therapy, pp. 37-72. New York: Marcel Dekker, Inc., 1997.
30. Gandhi, V., and Plunkett, W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res., 48: 329-334, 1988.
31. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Biochemical modulation of 1-β-D-arabinofuranosylcytosine for therapy of leukemias. Leuk. Lymphoma, 10 (Suppl.): 109-114, 1993.
32. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Kornblau, K., Pierce, S., Freireich, E. J, Deisseroth, A., and Keating, M. J. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol., 12: 671-678, 1994.
33. O'Brien, S., Kantarjian, H., Beran, M., Freireich, E., Kornblau, S., Koller, C., Lerner, S., Gilbreath, J., and Keating, M. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL). Blood, 88: 480a, 1996.
34. Hochester, H., Oken, M., Bennett, J., Wolf, B., Gordon, L., Raphael, B., Gencarelli, P., and Cassileth, P. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first-line therapy of low-grade non-Hodgkin's lymphoma. Blood, 84: 1517, 1994.
35. McLaughlin, P., Swan, F., Hagemeister, F., Cabanillas, F., Pate, O., Romaguera, J. E., Rodriguez, M. A., Redman, J. R., and Keating, M. Phase I study of the combination of fludarabine, mitoxantrone and dexamethasone in low-grade lymphoma. J. Clin. Oncol., 12: 575-579, 1994.
36. Yang, L-Y., Li, L., Keating, M. J., and Plunkett, W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol., 47: 1072-1079, 1995.
37. Seymour, J. F., Grigg, A., Szer, J., and Fox, R. Fludarabine, cisplatin and ara-C: an active regimen in patients with anthracycline-refractory intermediate-grade NHL. Blood, 209: 1995.
38. Reist, E. J., and Goodman, L. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry, 3: 15-18, 1964.
39. Gelfand, E. W., Lee, J. W. W., and Cohen, A. Sensitivity of T-leukemic cells to deoxyguanosine and arabinosylguanine. Adv. Exp. Med. Biol., 165: 309, 1984.
40. Kurtzberg, J., Keating, M., Moore, J., Gandhi, V., Blaney, S., Gold, S., Ernst, T., Henslee-Downey, J., Chang, A., Kisor, D., Plunkett, W., and Mitchell, B. 9-β-D-Arabinofuranosyl-6-methoxy-9H-guanine (GW50U; compound 506U) is highly active in patients with T-cell malignancies: results of a Phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood, 88: 669a, 1996.
41. Gandhi, V., Kisor, D. F., Rodriguez, C. O., Mitchell, B. S., Kurtzberg, J., Keating, M. J., and Plunkett, W. Pharmacokinetics of arabinosylguanine (ara-G) and its triphosphate (ara-GTP) during a Phase I trial of compound GW506U in refractory hematologic malignancies: correlation with response. Blood, 88: 670a, 1996.
42. Estey, E., Keating, M. J., McCredie, K. B., Freireich, E. J., and Plunkett, W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia (Baltimore), 4: 95-99, 1990.
43. Rodriguez, C. O., Jr., Legha, J. K., Estey, E., Keating, M. J., and Gandhi, V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin. Cancer Res., 3: 2107-2113, 1997.